Last reviewed · How we verify
HF Patients With LVADs Being Treated With SGLT2i
The main purpose of this study is to observe outcomes of sodium-glucose co-transporter 2 inhibitors (SGLT2i) in heart failure (HF) patients with left ventricular assist devices (LVAD).
Details
| Lead sponsor | University of Chicago |
|---|---|
| Phase | PHASE4 |
| Status | COMPLETED |
| Enrolment | 32 |
| Start date | Thu Sep 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Sun Aug 31 2025 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Heart Failure With Reduced Ejection Fraction
Interventions
- SGLT2i
- No SGLT2i
Countries
United States